Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biocryst Pharma Inc (NQ: BCRX )

9.685 USD +0.185 (+1.95%)
Official Closing Price Updated: 7:58 PM EDT, Apr 13, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biocryst Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
BioCryst Appoints Helen Thackray, M.D., to Board of Directors
From GlobeNewswire News Releases
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
BioCryst to Present at H.C. Wainwright Global Investment Conference
From GlobeNewswire News Releases
BioCryst Reports Second Quarter 2019 Financial Results
From GlobeNewswire News Releases
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
From GlobeNewswire News Releases
BioCryst to Report Second Quarter 2019 Financial Results on August 6
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2019 financial results on Tuesday, August 6, 2019. 
From GlobeNewswire News Releases
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees options to purchase an aggregate of... 
From GlobeNewswire News Releases
BioCryst Appoints Megan Sniecinski Chief Business Officer
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Megan Sniecinski as chief business officer. 
From GlobeNewswire News Releases
Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has begun enrollment of a Phase 1 trial of BCX9930, an oral Factor D inhibitor discovered and developed by BioCryst, for... 
From GlobeNewswire News Releases
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted four newly-hired employees options to purchase an aggregate of... 
From GlobeNewswire News Releases
BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies 2019 Healthcare Conference in New York on Wednesday, June 5, 2019 at 10:30 a.m. ET and the... 
From GlobeNewswire News Releases
BioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial
NDA filing on-track for Q4 2019 
From GlobeNewswire News Releases
BioCryst to Present at Bank of America Merrill Lynch Health Care Conference
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Wednesday, May 15, 2019 at 1:00... 
From GlobeNewswire News Releases
BioCryst Completes Phase 1 Clinical Trial of Galidesivir
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the completion of a randomized, placebo-controlled Phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers. In... 
From GlobeNewswire News Releases
BioCryst Reports First Quarter 2019 Financial Results
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the first quarter ended March 31, 2019 and provided a corporate update. 
From GlobeNewswire News Releases
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees options to purchase an aggregate of... 
From GlobeNewswire News Releases
BioCryst to Report First Quarter 2019 Financial Results on May 8
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2019 financial results on Wednesday, May 8, 2019. 
From GlobeNewswire News Releases
BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the H.C. Wainwright Global Life Sciences Conference in London on Monday, April 8, 2019 at 4:30 a.m. ET and... 
From GlobeNewswire News Releases
Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Sarepta Therapeutics, Inc.... 
From GlobeNewswire News Releases
BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2018, and provided a corporate update. 
From GlobeNewswire News Releases
BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company is advancing BCX9930, an oral Factor D inhibitor discovered and developed by BioCryst, into Phase 1 clinical development... 
From GlobeNewswire News Releases
BioCryst to Present at Barclays Global Healthcare Conference
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Barclays Global Healthcare Conference in Miami Beach, Florida on Tuesday, March 12, 2019 at 8:00 a.m.... 
From GlobeNewswire News Releases
BioCryst Reports ZENITH-1 Results With Oral BCX7353 Which Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response for Treatment of Acute HAE Attacks
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today reported additional topline data from the Phase 2 ZENITH-1 trial, including new data from the 250 mg and 500 mg dose cohorts. Data from the now... 
From GlobeNewswire News Releases
BioCryst to Report Fourth Quarter and Full Year 2018 Financial Results on March 4
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2018 financial results on Monday, March 4, 2019. 
From GlobeNewswire News Releases
Detailed Research: Economic Perspectives on Callon Petroleum, Summit Materials, Echo Global Logistics, BioCryst Pharmaceuticals, NEXEO SOLUTIONS, and NL Industries — What Drives Growth in Today's Comp
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Callon Petroleum Company... 
From GlobeNewswire News Releases
BioCryst Strengthens Cash Position With Flexible $100 Million Debt Facility
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced today that the company has entered into a $100 million secured loan facility (new loan facility) with MidCap Financial Trust (MidCap) pursuant to... 
From GlobeNewswire News Releases
BioCryst to Present ZENITH-1 Results at American Academy of Allergy, Asthma & Immunology Annual Meeting
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present an abstract including results from the ZENITH-1 study at the upcoming annual meeting of the American Academy... 
From GlobeNewswire News Releases
BioCryst Appoints Steve Aselage to Board of Directors
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Steve Aselage to its board of directors. 
From GlobeNewswire News Releases
BioCryst to Present at 37th Annual J.P. Morgan Healthcare Conference
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 1:30... 
From GlobeNewswire News Releases
BioCryst Initiates Phase 1 Clinical Trial of Galidesivir
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the dosing of the first subject in a randomized, placebo-controlled phase 1 clinical trial to evaluate intravenous (IV) galidesivir in... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account